Roche terminates slow-running HPV vaccine alliance with Transgene
This article was originally published in Scrip
Executive Summary
Roche has terminated its 2007 alliance agreement with Transgene of France for exclusive global development and commercialisation rights to TG4001 (RG3484), a therapeutic vaccine candidate to treat diseases caused by the human papilloma virus (HPV).